Atika Capital Management LLC Uni Qure N.V. Transaction History

Atika Capital Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$45.06 - $67.74 $991,320 - $1.49 Million	-22,000 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$40.01 - $73.97 $560,140 - $1.04 Million	14,000 Added 175.0%	22,000 $1.04 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $297,040 - $596,960	8,000 New	8,000 $573,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.